Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
Puma JA, Banko LT, Pieper KS, Sacchi TJ, O'Shea JC, Dery JP, Tcheng JE. Puma JA, et al. Among authors: tcheng je. J Am Coll Cardiol. 2006 Feb 21;47(4):715-8. doi: 10.1016/j.jacc.2005.08.075. Epub 2006 Jan 26. J Am Coll Cardiol. 2006. PMID: 16487833 Free article.
Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
Dery JP, Campbell ME, Mathias J, Pieper KS, Harrington RA, Madan M, Gibson CM, Tolleson TR, O'Shea JC, Tcheng JE; ESPRIT Investigators. Dery JP, et al. Among authors: tcheng je. Catheter Cardiovasc Interv. 2007 Jul 1;70(1):43-50. doi: 10.1002/ccd.21059. Catheter Cardiovasc Interv. 2007. PMID: 17203469 Clinical Trial.
Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.
O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, Strony J, Tcheng JE; ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial). O'Shea JC, et al. Among authors: tcheng je. JAMA. 2001 May 16;285(19):2468-73. doi: 10.1001/jama.285.19.2468. JAMA. 2001. PMID: 11368699 Clinical Trial.
292 results